New hope for kidney cancer patients after first treatment fails
NCT ID NCT06035224
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests a combination of two drugs, cadonilimab and lenvatinib, in people with advanced clear cell kidney cancer whose disease got worse after initial immunotherapy. The goal is to see if this combo can shrink tumors or stop them from growing. About 28 adults will take part, and they will receive the drugs until their cancer progresses or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Renji Hospital
Shanghai, Shanghai Municipality, 200123, China
Conditions
Explore the condition pages connected to this study.